BridgeBio Pharma Cost of Goods Sold 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly cost of goods sold history and growth rate from 2018 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- BridgeBio Pharma cost of goods sold for the quarter ending June 30, 2024 was $0.001B, a 0.17% decline year-over-year.
- BridgeBio Pharma cost of goods sold for the twelve months ending June 30, 2024 was $0.002B, a 9.26% decline year-over-year.
- BridgeBio Pharma annual cost of goods sold for 2023 was $0.002B, a 28.77% decline from 2022.
- BridgeBio Pharma annual cost of goods sold for 2022 was $0.003B, a 10.28% increase from 2021.
- BridgeBio Pharma annual cost of goods sold for 2021 was $0.003B, a INF% increase from 2020.
BridgeBio Pharma Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$3 |
| 2021 |
$3 |
| 2020 |
$ |
| 2019 |
$3 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$1 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
$3 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.045B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
